MAPLE GROVE, Minn., May 9, 2017 /PRNewswire/ -- NxThera, Inc., a medical device company pioneering the application of its convective radiofrequency thermotherapy to treat endourological conditions, today announced the company's Rezūm System has been used to safely and effectively treat more than 10,000 men suffering from benign prostatic hyperplasia (BPH) across the U.S. and Europe.
"Our mission is to transform the BPH treatment experience for urologists and their patients," said Bob Paulson, president and CEO of NxThera. "With more than 12 million men in the U.S. suffering from BPH, the Rezūm System offers a versatile, durable and cost-effective alternative for men who are unhappy on or who discontinued their BPH medications, or who are choosing 'watchful waiting' rather than undergo a surgical procedure to treat their BPH. We are honored that more than 500 urologists in the U.S., together with their urologist colleagues in Germany, Sweden and England, have used the Rezūm System to treat more than 10,000 men suffering from the debilitating lower urinary tract symptoms of BPH and significantly improve their patients' quality of life."
"Since my Rezūm procedure, I've been free from having to know where the bathroom is right away," said patient James Huber. "It worked beautifully and there have been no side effects. I don't have to take pills, and don't have to pay for them. The end result is freedom, and when you're 75, that becomes a really important issue. It gives you the freedom you never thought you would have again."
"Based on the conservation of sexual function and efficacy in treating LUTS/BPH, Rezūm could be offered as first-line treatment in lieu of drugs for patients with moderate to severe LUTS," said Dr. Kevin McVary, professor and chair, Division of Urology, Southern Illinois University School of Medicine in Springfield, Ill.
BPH is one of the top 10 most common and costly diseases in the U.S., affecting more than 12 million American men aged 50 or older, with nearly 800,000 new diagnoses each year. BPH causes significant quality of life issues including waking up multiple times during the night to urinate, frequency, urgency, irregular and weak urinary flow, anxiety, challenges with sexual function and limitation in daily activities. The Rezūm System uses radiofrequency current to create thermal energy that is convectively delivered to obstructive prostate tissue through targeted, precise treatments. The treated tissue is then resorbed by the body's immune system which alleviates the symptoms of BPH and improves patients' quality of life and ability to urinate, while preserving sexual function.
Urology experts will present five abstracts reporting the data from clinical studies they conducted on the Rezūm System to treat BPH during the 2017 American Urological Association (AUA) annual meeting in Boston May 13 - 15, 2017. These presentations will include Dr. Claus Roehrborn, chair of UT Southwestern Urology Department, presenting the two-year outcomes from the company's randomized controlled, level one pivotal study of the Rezūm System to relieve LUTS caused by BPH. Dr. Nikhil Gupta of Southern Illinois University will present clinical data demonstrating the effectiveness of the Rezūm System to treat BPH in (i) obese men, while preserving erectile and ejaculatory function (which received the "Best Abstract Award" from the AUA), (ii) men who are in retention as a result of their BPH, and (iii) men compared to the outcomes data from the National Institute of Health sponsored "Medical Therapy of Prostatic Symptoms" (MTOPS) study. In addition, Dr. Tobias Köhler, most recently of Southern Illinois University and now of The Mayo Clinic, will present the Rezūm procedure as part of the Plenary Prime Time BPH Surgical Techniques session.
For more information about the Rezūm System, visit www.Rezūm.com.
NxThera pioneered its convective radiofrequency thermotherapy platform technology to treat a variety of endourological conditions, beginning with BPH. NxThera's FDA-cleared Rezūm System is a next-generation transurethral needle ablation system using radiofrequency to create thermal energy that is convectively delivered to obstructive prostate tissue in targeted, precise thermotherapy treatments, with minimal discomfort, to improve the symptoms of BPH and quality of life. Founded in 2008, NxThera is located in Maple Grove, Minn. For more information, visit www.Rezūm.com.
SOURCE NxThera, Inc.